Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease. Zhou, L., Chen, H., Wen, Q., & Zhang, Y. European Journal of Gastroenterology & Hepatology, 24(6):695–701, June, 2012. ![Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Objective The study is carried out to identify the expression pattern of indoleamine 2,3-dioxygenase (IDO) in human Crohn’s disease and ulcerative colitis and to investigate the effect of different therapies (salicylates, steroids, and antitumor necrosis factor antibody) on the intestinal expression of IDO. Methods Immunohistochemistry was used. A total of 10 high power fields were counted for each patient. Results IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn’s disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy. Conclusion IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.
@article{zhou_indoleamine_2012,
title = {Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease},
volume = {24},
issn = {0954-691X},
url = {https://journals.lww.com/eurojgh/Abstract/2012/06000/Indoleamine_2,3_dioxygenase_expression_in_human.13.aspx},
doi = {10.1097/MEG.0b013e328351c1c2},
abstract = {Objective
The study is carried out to identify the expression pattern of indoleamine 2,3-dioxygenase (IDO) in human Crohn’s disease and ulcerative colitis and to investigate the effect of different therapies (salicylates, steroids, and antitumor necrosis factor antibody) on the intestinal expression of IDO.
Methods
Immunohistochemistry was used. A total of 10 high power fields were counted for each patient.
Results
IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn’s disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy.
Conclusion
IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.},
language = {en-US},
number = {6},
urldate = {2020-06-07},
journal = {European Journal of Gastroenterology \& Hepatology},
author = {Zhou, Liping and Chen, Huan and Wen, Quan and Zhang, Yan},
month = jun,
year = {2012},
keywords = {Adult, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Antigens, CD, Antigens, Differentiation, Myelomonocytic, CD11c Antigen, Colitis, Ulcerative, Crohn Disease, Epithelial Cells, Female, Gastrointestinal Agents, Glucocorticoids, Humans, Immunoenzyme Techniques, Indoleamine-Pyrrole 2,3,-Dioxygenase, Inflammatory Bowel Diseases, Infliximab, Intestinal Mucosa, Male, Middle Aged, Salicylates, Toll-Like Receptor 4, Tumor Necrosis Factor-alpha},
pages = {695--701},
}
Downloads: 0
{"_id":"mKCoHTzGDbRtpv9yh","bibbaseid":"zhou-chen-wen-zhang-indoleamine23dioxygenaseexpressioninhumaninflammatoryboweldisease-2012","author_short":["Zhou, L.","Chen, H.","Wen, Q.","Zhang, Y."],"bibdata":{"bibtype":"article","type":"article","title":"Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease","volume":"24","issn":"0954-691X","url":"https://journals.lww.com/eurojgh/Abstract/2012/06000/Indoleamine_2,3_dioxygenase_expression_in_human.13.aspx","doi":"10.1097/MEG.0b013e328351c1c2","abstract":"Objective The study is carried out to identify the expression pattern of indoleamine 2,3-dioxygenase (IDO) in human Crohn’s disease and ulcerative colitis and to investigate the effect of different therapies (salicylates, steroids, and antitumor necrosis factor antibody) on the intestinal expression of IDO. Methods Immunohistochemistry was used. A total of 10 high power fields were counted for each patient. Results IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn’s disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy. Conclusion IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.","language":"en-US","number":"6","urldate":"2020-06-07","journal":"European Journal of Gastroenterology & Hepatology","author":[{"propositions":[],"lastnames":["Zhou"],"firstnames":["Liping"],"suffixes":[]},{"propositions":[],"lastnames":["Chen"],"firstnames":["Huan"],"suffixes":[]},{"propositions":[],"lastnames":["Wen"],"firstnames":["Quan"],"suffixes":[]},{"propositions":[],"lastnames":["Zhang"],"firstnames":["Yan"],"suffixes":[]}],"month":"June","year":"2012","keywords":"Adult, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Antigens, CD, Antigens, Differentiation, Myelomonocytic, CD11c Antigen, Colitis, Ulcerative, Crohn Disease, Epithelial Cells, Female, Gastrointestinal Agents, Glucocorticoids, Humans, Immunoenzyme Techniques, Indoleamine-Pyrrole 2,3,-Dioxygenase, Inflammatory Bowel Diseases, Infliximab, Intestinal Mucosa, Male, Middle Aged, Salicylates, Toll-Like Receptor 4, Tumor Necrosis Factor-alpha","pages":"695–701","bibtex":"@article{zhou_indoleamine_2012,\n\ttitle = {Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease},\n\tvolume = {24},\n\tissn = {0954-691X},\n\turl = {https://journals.lww.com/eurojgh/Abstract/2012/06000/Indoleamine_2,3_dioxygenase_expression_in_human.13.aspx},\n\tdoi = {10.1097/MEG.0b013e328351c1c2},\n\tabstract = {Objective \n The study is carried out to identify the expression pattern of indoleamine 2,3-dioxygenase (IDO) in human Crohn’s disease and ulcerative colitis and to investigate the effect of different therapies (salicylates, steroids, and antitumor necrosis factor antibody) on the intestinal expression of IDO.\n Methods \n Immunohistochemistry was used. A total of 10 high power fields were counted for each patient.\n Results \n IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn’s disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy.\n Conclusion \n IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.},\n\tlanguage = {en-US},\n\tnumber = {6},\n\turldate = {2020-06-07},\n\tjournal = {European Journal of Gastroenterology \\& Hepatology},\n\tauthor = {Zhou, Liping and Chen, Huan and Wen, Quan and Zhang, Yan},\n\tmonth = jun,\n\tyear = {2012},\n\tkeywords = {Adult, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Antigens, CD, Antigens, Differentiation, Myelomonocytic, CD11c Antigen, Colitis, Ulcerative, Crohn Disease, Epithelial Cells, Female, Gastrointestinal Agents, Glucocorticoids, Humans, Immunoenzyme Techniques, Indoleamine-Pyrrole 2,3,-Dioxygenase, Inflammatory Bowel Diseases, Infliximab, Intestinal Mucosa, Male, Middle Aged, Salicylates, Toll-Like Receptor 4, Tumor Necrosis Factor-alpha},\n\tpages = {695--701},\n}\n\n","author_short":["Zhou, L.","Chen, H.","Wen, Q.","Zhang, Y."],"key":"zhou_indoleamine_2012","id":"zhou_indoleamine_2012","bibbaseid":"zhou-chen-wen-zhang-indoleamine23dioxygenaseexpressioninhumaninflammatoryboweldisease-2012","role":"author","urls":{"Paper":"https://journals.lww.com/eurojgh/Abstract/2012/06000/Indoleamine_2,3_dioxygenase_expression_in_human.13.aspx"},"keyword":["Adult","Anti-Inflammatory Agents","Non-Steroidal","Antibodies","Monoclonal","Antigens","CD","Antigens","Differentiation","Myelomonocytic","CD11c Antigen","Colitis","Ulcerative","Crohn Disease","Epithelial Cells","Female","Gastrointestinal Agents","Glucocorticoids","Humans","Immunoenzyme Techniques","Indoleamine-Pyrrole 2","3","-Dioxygenase","Inflammatory Bowel Diseases","Infliximab","Intestinal Mucosa","Male","Middle Aged","Salicylates","Toll-Like Receptor 4","Tumor Necrosis Factor-alpha"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/tplas","dataSources":["YLgywGcXWx96vKKaB"],"keywords":["adult","anti-inflammatory agents","non-steroidal","antibodies","monoclonal","antigens","cd","antigens","differentiation","myelomonocytic","cd11c antigen","colitis","ulcerative","crohn disease","epithelial cells","female","gastrointestinal agents","glucocorticoids","humans","immunoenzyme techniques","indoleamine-pyrrole 2","3","-dioxygenase","inflammatory bowel diseases","infliximab","intestinal mucosa","male","middle aged","salicylates","toll-like receptor 4","tumor necrosis factor-alpha"],"search_terms":["indoleamine","dioxygenase","expression","human","inflammatory","bowel","disease","zhou","chen","wen","zhang"],"title":"Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease","year":2012}